New Treatments for Type 2 Diabetes: Cardiovascular Protection Beyond Glucose Lowering?
Dilshani Jayawardene, Glenn M Ward, David N O'Neal, Geetha Theverkalam, Andrew I MacIsaac, Richard J MacIsaac
Heart, Lung and Circulation | ELSEVIER SCIENCE INC | Published : 2014
Richard MacIsaac, Glenn Ward and David O'Neal have participated in clinical trials involving the use of saxagliptin, lixisenatide and liragultide. Richard MacIsaac has received honoraria for lectures from Eli lily, Novo Nordisk, Sanofi Aventis, Astra Zeneca, Merck Sharp & Dohme and Norvartis over the last two years. He has received research grants from Novo Nordisk in 2011. He attended one advisory board meeting for Boehringer- Ingelheim in 2013.